A lot has been happening lately at AngioSoma Inc (OTCMKTS: SOAN), including a tumbling stock affected by weak investor sentiment. However, the company has initiated a series of remedial activities as well as the introduction of new products. As things stand now, the company efforts are paying off as the stock is beginning to edge upwards.
What is the performance of the share price?
In the month of May, SOAN has experienced an uplifting spike in trading volume of its stock. The latest numbers show that traders moved around 11 million shares on Monday trading session. As such, the surge in volume pushed the stock closer to $0.02, a level last touched in March 2019. If the share price continues to rally, it will soon breach the day’s range which lies between $0.0085 and $0.0139.
Nonetheless, the stock still has a mountain to climb before it has a chance to break out above the 52-week high of $0.6. Meantime, the stock is likely to bounce back especially after bottoming out at $0.007 on Wednesday, May 15, 2019. Since then, the bulls are pushing the share price higher each day. To put this in context, SOAN stock closed at $0.013 on May 20 which represents a gain of about 85.7% in the last three trading days.
The likelihood of the current bull market holding strong is reaffirmed by the developments at the company. Just last month, a SOAN subsidiary acquired a facility in Texas which is expected to facilitate its operations. The company said that the facility will help the subsidiary to establish itself in the state and, as such, the company will get an opportunity to expand its market. Notably, the facility will be used as a treatment center for diabetics in the San Antonio area and its surroundings. The treatment will target patients with diabetic neuropathy.
What does AngioSoma, Inc. do?
Based in Nevada, AngioSoma, Inc. is a company which operates in the biotech industry and produces supplements under a common identity called SomaCeuticals™. Notably, the supplements fall under the cosmeceuticals, pharmaceuticals and nutraceuticals categories. Bundling the supplements under a common identity is aimed at facilitating the smooth transition of the products from development to commercialization.
Key products under the SomaCeuticals™ brand name include Liprostin which targets patients with peripheral artery disease (PAD). Other products include Transdermal PGE-1 Patch which facilitates the delivery of Liprostin. Additional products include OMNICATH I $ II catheters among other products.
Launch of an e-commerce website
Besides developing products through extensive research, AngioSoma was also targeting to engage directly with its consumers. That meant the removal of any kind of middle parties who would facilitate the marketing and distribution of the products to the market. In this light, the company went ahead and launched a platform where consumers will access SomaCeuticals™ branded products directly from the developer.
The e-commerce website will offer a range of products from AngioSoma but the major one will be StemStrength Deluxe AM and PM, a workout amplifier. Notably, the company created the products for both genders and they will all be available on the platform. Other products available on the website include Eye Serum, Anti-Wrinkle Serum, and Anti-Aging Crème. All these products fall under the beauty products category within the SomaCeuticals™ family.
The primary focus of the website is to increase the visibility of the products SOAN develops. Commenting in this respect, Alex Blankenship, the President of SOAM said,
“We are excited about our new website. The greater visibility for offering our supplements for sale to the public is a substantial step forward.”
Advertising in US airports
Further efforts at product visibility saw SOAN sign an advertising agreement with ClearTV Media USA. In particular, ClearTV will display its products on healthcare and airport TV for a period of one year. As such, AngioSoma products will appear on away-from-home venues where high exposure is guaranteed.
According to Blankenship, the agreement is expected to drive up demand for the workout amplifier. Further, the President of AngioSoma expressed his delight that the agreement will offer the much-needed visibility of the company’s products.
“The greater visibility for offering our supplements for sale to the public is a meaningful step forward,” he said.
Further development of lead products
During May 2018, the company revealed that a patent application they had lodged with the US Patent Office was successful. The patent covered the development of Liprostin, a flagship product for the treatment of PAD. Notably, the company is waiting to complete the Phase 3 clinical trials before full commercialization.
Statistics indicate that by 2018, over 8 million Americans were diagnosed with PAD. Many of PAD patients are diabetics and the lack of sufficient solutions provides an unmet medical need which SOAN seeks to satisfy. The company is staring at annual revenues in the range of $212 billion to $389 billion.
AngioSoma has been weak since February and during that period, it traded at sub-$0.01 levels almost entirely. However, the recent jump in volume traded is evidence that the bulls might finally be streaming in this direction. Further, the recent developments should improve investor sentiments positively and lead to a sustained bull run in SOAN.
We will be updating our subscribers as soon as we know more. For the latest updates on SOAN, sign up below!
Disclosure: We have no position in SOAN and have not been compensated for this article.